title: Re: Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
authors.affiliation: Sydney Institute of Vision Science, 13/187 Macquarie Street, Sydney, NSW, 2000, Australia.|Save Sight Institute, University of Sydney, Sydney, NSW, Australia.
authors.forename: Bobak
authors.initials: B
authors.lastname: Bahrami
authors.affiliation: Sydney Institute of Vision Science, 13/187 Macquarie Street, Sydney, NSW, 2000, Australia.
authors.forename: Thomas
authors.initials: T
authors.lastname: Hong
authors.affiliation: Sydney Institute of Vision Science, 13/187 Macquarie Street, Sydney, NSW, 2000, Australia. achang@sydneyretina.com.au.|Save Sight Institute, University of Sydney, Sydney, NSW, Australia. achang@sydneyretina.com.au.
authors.forename: Andrew
authors.initials: A
authors.lastname: Chang
mesh_terms: D000068258:Bevacizumab; D003930:Diabetic Retinopathy; D006801:Humans; D008269:Macular Edema; D040262:Receptors, Vascular Endothelial Growth Factor; D011993:Recombinant Fusion Proteins
chemical_list: D011993:Recombinant Fusion Proteins; C533178:aflibercept; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor